Staedtisches Klinikum Karlsruhe gGmbH
- Address
- lock Available on a paid plan
Hematologic Malignancies and Blood Disorders
At Staedtisches Klinikum Karlsruhe gGmbH, a major focus is on hemic and lymphatic diseases, especially acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. The studies are designed to test new treatment strategies, refine risk-adapted care, and improve long-term disease control.
- Advancing treatment options for acute leukemias in both adults and children
- Evaluating new approaches for lymphoma, including relapsed and high-risk disease
- Testing therapies aimed at improving remission depth and survival in multiple myeloma
These trials often compare newer combinations with established care to see whether outcomes can be improved while keeping treatment manageable for patients.
Pediatric and Adolescent Oncology
The site also supports extensive research in pediatric neoplasms, with studies in neuroblastoma, medulloblastoma, ependymoma, and childhood renal tumors. This work aims to improve cure rates, reduce relapse risk, and better tailor therapy to disease risk.
- Investigating treatment strategies for high-risk neuroblastoma
- Studying outcome improvement in medulloblastoma and ependymoma
- Refining care for childhood kidney tumors and other rare pediatric cancers
Research in this area focuses on finding more effective and safer treatment paths for children and adolescents with serious cancers.
Breast, Gynecologic, and Gastrointestinal Cancers
Clinical trials at this hospital include several solid tumor programs in neoplasms, particularly breast cancer, ovarian cancer, gastric cancer, colorectal cancer, and biliary tract cancer. The research is aimed at improving survival, reducing recurrence, and identifying better ways to personalize treatment.
- Testing new treatment combinations for early and triple-negative breast cancer
- Evaluating therapies for advanced ovarian cancer and biliary tract cancer
- Studying adjuvant approaches in colon cancer and treatment options for gastric cancer
These studies help determine whether newer cancer treatments can improve outcomes compared with standard care.
Immune, Transplant, and Cellular Therapy Research
Another important area is immune system diseases, including trials related to graft-versus-host disease, stem cell transplantation, and long-term follow-up after gene-modified T-cell treatment. This research explores how to improve immune-based therapies and make transplant care safer and more effective.
- Assessing long-term outcomes after cellular immunotherapy
- Improving conditioning and supportive care around allogeneic transplantation
- Studying strategies to reduce complications such as graft-versus-host disease
These trials are especially relevant for patients with difficult-to-treat blood cancers who may benefit from advanced immune-based approaches.
Cardiovascular, Kidney, and Metabolic Disease Studies
Beyond oncology, the site is also involved in research on cardiovascular diseases and nutritional and metabolic diseases, including chronic kidney disease, hypertension, and related cardiorenal conditions. The goal is to improve disease control, protect organ function, and support better long-term health outcomes.
- Evaluating treatments for chronic kidney disease and albuminuria
- Studying therapies for patients with hypertension and kidney-related risk
- Exploring approaches that may reduce cardiovascular and kidney complications
These trials broaden the research portfolio at Medizinische Klinik III by addressing important non-cancer conditions alongside oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 6 therapeutic areas and 15 of 151 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 146 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1GPOH gGmbH6active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH6trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Staedtisches Klinikum Karlsruhe gGmbH
lock Showing 1 of 60 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). | AstraZeneca AB | Phase III | Not Recruiting | Feb 2019 | Apr 2026 |
IMP list
lock Showing 1 of 151 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 15 | Unknown | 2015-06-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.